Feed / SDGR

Schrödinger, Inc.

SDGR

Healthcare · 18.92 -1.5% today

Isolated · not yet confirmedMarket checked 11 Sept, 15:05 GMT-4

Market read

Schrödinger, Inc.'s current read is isolated; its market group is not confirming.

No new filing conclusion is available. 0 of 39 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 13 directly disclosed connections are confirming.

Company-1.5% todayVolume comparison unavailable
Market group0 of 39 activeCloud and AI Solutions · unavailable
Disclosed network0 of 8 confirmingNo filing-linked name is confirming now
What would change this read
  • SDGR's market-adjusted activity becomes unusual and at least one connected name confirms.

Invalidation: The isolated read changes if SDGR's group or a disclosed connection begins moving with it.

Watch this read

Research brief

The story so far

Healthcare · Health Information Services

No new filing conclusion is available. 0 of 39 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 13 directly disclosed connections are confirming.

Evidence that supports

No thresholded supportive filing evidence is available yet.

Evidence that challenges

No thresholded adverse filing evidence is available yet.

What would clarify the read
  • SDGR's market-adjusted activity becomes unusual and at least one connected name confirms.

Company research

Understand the business, not just the ticker

As of Sep 11, 2026
Business model and earnings drivers

Use the company’s filings to identify the few operating, demand, cost, capital and regulatory variables that determine its earnings power.

Key research questions
  • Which operating variable is changing?
  • Is that change durable, cyclical or one-off?
  • What evidence would disprove the current interpretation?
Annual periods7
Price observations319
Usable filing statements155
Verified relationships13
Evidence supporting the case
  • Latest annual revenue changed +23.3% year over year.
  • Operating margin changed +35.6 percentage points in the latest annual period.
  • Net margin changed +49.8 percentage points in the latest annual period.
  • Macroeconomic conditions has repeated favorable evidence across 4 filings.
Evidence challenging the case
  • Product pipeline and R&D has repeated adverse evidence across 4 filings.
Questions before a position
  • EV/sales is 17% above the available filing-peer median; determine whether growth and quality justify the difference.
Longer-term price context

Price as of Sep 10, 2026

18.76
6m+55.5%12m-5.2%24m
Annual trajectory

Reported annual revenue and per-share history. This is accounting history, not a forecast.

PeriodRevenueYoYDiluted EPSShare change
2021-12-31$137.9M+27.6%$-1.42+17.6%
2022-12-31$181.0M+31.2%$-2.10+0.8%
2023-12-31$216.7M+19.7%$0.54+5.4%
2024-12-31$207.5M-4.2%$-2.57-3.1%
2025-12-31$255.9M+23.3%$-1.41+1.1%

What management says matters

Persistent and emerging business drivers

Foreign exchangemixed · 4 filings
Other Income Three Months Ended March 31, 2026 2025 Change (in thousands) Other income $ 2,663 $ 4,204 $ (1,541) The decrease in other income during the three months ended March 31, 2026 compared to the three months ended March 31, 2025 was attributable to un…
10-Q · May 5, 2026
Legal and regulatory exposurepositive · 4 filings
We expect to continue to incur additional expenses as a result of operating as a public company, including costs to comply with the rules and regulations applicable to companies listed on a U.S.
10-Q · May 5, 2026
Macroeconomic conditionspositive · 4 filings
Trade tensions and conflicts between the United States and China have been escalated in recent years and, as such, we are exposed to the possibility of product supply disruption and increased costs and expenses in the event of changes to the laws, rules, regu…
10-K · Feb 25, 2026
Product pipeline and R&Dnegative · 4 filings
The increase in all other research and development expense of $1.1 million during the three months ended March 31, 2026 as compared to the three months ended March 31, 2025 was attributable to increases of approximately $1.0 million in personnel-related expen…
10-Q · May 5, 2026

Valuation discipline

Descriptive valuation snapshot

Price/sales 5.4× · EV/sales 4.5×. Comparisons use only industry-matched filing peers.

Scenario scaffold

Mechanical 2.0-year scenarios are available as editable assumptions, not consensus.

Price action

How the market is pricing the story

18.92-1.5% today

Jodie does not have enough daily observations to draw a useful short-term chart for this asset. The latest quoted price was checked 11 Sept, 15:05 GMT-4; this is a coverage limitation, not a flat-price conclusion.

Developments

No sourced recent-development timeline yet

Jodie has not returned a relevant primary source or news item for SDGR. This is an evidence-coverage gap, not a conclusion that nothing material happened.

Business and financial condition

Reported financial figures are not available yet

Jodie has not returned structured SEC XBRL fundamentals for this asset. This is a coverage limitation, not an assessment of the business or its financial health.

Filing analysis

No comparable filing assessment is available yet

Jodie has not yet found a suitable current-versus-prior filing comparison for SDGR. This does not mean the latest filing was neutral or immaterial.

Business ecosystem

The relationships behind SDGR

Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.

Depends on

NVSNovartis AGcustomerMay 5, 2026

The Company assessed the research collaboration and license agreement in accordance with Topic 606 and concluded that Novartis is a customer based on the agreement structure.

NVSNovartis AGpartnerFeb 25, 2026

In November 2024, we entered into a research collaboration and license agreement with Novartis Pharma AG, or Novartis, pursuant to which we and Novartis agreed to collaborate on the discovery, research and preclinical development of small molecule compounds f…

Depended on by

ABSIAbsci CorporationcompetitorNov 12, 2025

AI-enabled small molecule design) that may seek to develop antibody design capabilities, such as Recursion Pharmaceuticals, Inc., Relay Therapeutics, Inc., Isomorphic Labs Limited, and Schrodinger, Inc., among others; and; • we may face competition from acade…

Filing peers

Companies whose filings use similar operating language.

Open the three relationships above to see Jodie’s filing proof. Pro unlocks 14 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →

What is moving around it

Live connections

SDGR is currently a Follower in the organic co-movement group Cloud and AI Solutions. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.

This group is retained as the last observed read for SDGR; it is not active in the latest market snapshot.

Context history

Theme membership history

No durable theme membership has been observed for this name yet.